

Effective January 1, 2023

NOTICE TO HOLDERS OF TRUST CLAIMS

PLEASE TAKE NOTICE that pursuant to the Second Amendment to the First Amended United Gilsonite Laboratories Asbestos Personal Injury Trust Distribution Procedures, adopted effective February 27, 2018, the Trust shall annually adjust for inflation the Scheduled Values, Average Values and Maximum Values for the compensable Disease Levels as set forth in the First Amended United Gilsonite Laboratories Asbestos Personal Injury Trust Distribution Procedures (as amended, the “TDP”) based on the Consumer Price Index for All Urban Consumers (“CPI-U”) published by the United States Department of Labor, Bureau of Labor Statistics.

Pursuant to Sections 5.2(a)(3) and 5.2(b)(3) of the TDP, as amended, the Trustee has adjusted the Scheduled Values, Average Values, and Maximum Values for the compensable Disease Levels set forth in Section 5.2(b)(3), to account for inflation using the CPI-U for the period from June 2016, when the Trust began paying claims, through December 2022.

Accordingly, please take notice that the below adjusted Scheduled Values, Average Values, and Maximum Values for claims involving Disease Levels I – VIII shall apply to all offers made by the Trust from the date of this Notice. For the avoidance of doubt, the adjusted Scheduled Values, Average Values, and Maximum Values do not trigger supplemental payments under Section 4.3 of the TDP.

Scheduled Disease	Scheduled Value	Average Value	Maximum Value
Mesothelioma (Level VIII)	\$246,448	\$277,255	\$492,898
Lung Cancer 1 (Level VII)	\$25,877	\$27,725	\$36,967
Lung Cancer 2 (Level VI)	N/A	\$14,786	\$19,100
Other Cancer (Level V)	\$11,090	\$11,090	\$11,090
Severe Asbestosis (Level IV)	\$14,786	\$15,404	\$18,484
Asbestosis/Pleural Disease (Level III)	\$1,849	\$1,849	\$1,849
Asbestosis/Pleural Disease (Level II)	\$1,110	\$1,110	\$1,110
Other Asbestos Disease (Level I)	\$0	\$0	\$0